Autres langues Lundbeck Wiener Boerse

Actions

LUNA

DK0061804697

Produits pharmaceutiques

Cours en clôture Wiener Boerse 18/09/2026			Varia. 5j.	Varia. 1 janv.
5,420 ^EUR	+2,65%		-7,67%	+12,22%

11/09	Lundbeck : l'asedebart obtient la désignation de médicament orphelin de la FDA pour le syndrome de Cushing endogène	MT
11/09	Lundbeck obtient le statut de médicament orphelin aux États-Unis pour l'asedebart dans le traitement du syndrome de Cushing	FW

Autres langues

17/09	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
16/09	H. Lundbeck A/S Receives Marketing Authorization for Vyepti (Eptinezumab) in Japan for Prevention of Migraine Attacks
16/09	H. Lundbeck's Vyepti Wins Marketing Regulatory Nod in Japan
16/09	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks
15/09	H. Lundbeck A/S Completes Randomization In DEEp SEA Phase III Trial Of Bexicaserin In Dravet Syndrome
15/09	Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
11/09	Lundbeck's Asedebart Gets US FDA Orphan Drug Designation for Endogenous Cushing's Syndrome
11/09	The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
03/09	H. Lundbeck A/S Highlights Mechanistic Insights and Clinical Data on Bexicaserin At the European Epilepsy Congress
03/09	Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
24/08	Lundbeck's Obtains Orphan Designation in EU for Investigational Treatment for Cushing's Syndrome
24/08	European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
20/08	Cancer vaccines finally garner the spotlight
19/08	H Lundbeck : Q2 beat, but pipeline execution remains non-negotiable
19/08	Danish Pharma H. Lundbeck Expects No Slowdown for Primary Growth Driver Brands
19/08	H. Lundbeck A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
19/08	H. Lundbeck's Major Shareholder Kicks Off Voluntary Share Exchange Offer
19/08	Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
19/08	Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
19/08	H. Lundbeck A/S Maintains Earnings Guidance for the Year 2026
11/08	Moberg Pharma Appoints Business, Medical Chiefs
23/07	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, Investigational Orexin 2 Receptor Agonist for Narcolepsy
23/07	Lundbeck Secures US FDA Fast Track Designation for Narcolepsy Drug
23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
20/07	H. Lundbeck A/S Completes Randomization In DEEp OCEAN Phase III Clinical Trial Evaluating Bexicaserin For Treatment Of Seizures Associated With Developmental And Epileptic Encephalopathies